STING Gene

STING (TMEM173) — Stimulator of Interferon Genes

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | STING (TMEM173) |
| Full Name | Stimulator of Interferon Genes |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 340061 |
| OMIM ID | 612374 |
| Ensembl ID | ENSG00000184584 |
| UniProt ID | Q86WV1 |
| Encoded Protein | STING protein (379 aa) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease |

</div>

Overview

STING (Stimulator of Interferon Genes), also known as TMEM173, is a transmembrane protein that serves as the central signaling hub for the cGAS-STING pathway, one of the most important innate immune sensing mechanisms in eukaryotic cells. This pathway detects cytosolic DNA and triggers type I interferon responses, inflammatory cytokine production, and autophagy—responses that are protective against viral and bacterial pathogens but become pathological when chronically activated in the brain.

The cGAS-STING pathway has emerged as a critical mechanism in neurodegenerative disease pathogenesis. Since the initial discoveries linking this pathway to Alzheimer's disease in 2019-2020, a rapidly growing body of evidence implicates chronic STING activation as a major driver of neuroinflammation, microglial senescence, and neuronal dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [@xie2023][@sliter2023][@guo2022][@mathur2021].

Molecular Biology

STING (TMEM173) — Stimulator of Interferon Genes

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | STING (TMEM173) |
| Full Name | Stimulator of Interferon Genes |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 340061 |
| OMIM ID | 612374 |
| Ensembl ID | ENSG00000184584 |
| UniProt ID | Q86WV1 |
| Encoded Protein | STING protein (379 aa) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease |

</div>

Overview

STING (Stimulator of Interferon Genes), also known as TMEM173, is a transmembrane protein that serves as the central signaling hub for the cGAS-STING pathway, one of the most important innate immune sensing mechanisms in eukaryotic cells. This pathway detects cytosolic DNA and triggers type I interferon responses, inflammatory cytokine production, and autophagy—responses that are protective against viral and bacterial pathogens but become pathological when chronically activated in the brain.

The cGAS-STING pathway has emerged as a critical mechanism in neurodegenerative disease pathogenesis. Since the initial discoveries linking this pathway to Alzheimer's disease in 2019-2020, a rapidly growing body of evidence implicates chronic STING activation as a major driver of neuroinflammation, microglial senescence, and neuronal dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [@xie2023][@sliter2023][@guo2022][@mathur2021].

Molecular Biology

Gene Structure and Protein Architecture

The TMEM173 gene spans approximately 37 kb on the forward strand of chromosome 5q31.2 and consists of 6 exons encoding a 379-amino acid transmembrane protein. STING is composed of several functional domains:

• N-terminal transmembrane domain (residues 1-150): Anchors the protein to the endoplasmic reticulum (ER) membrane
• DNA sensing binding domain (residues 155-341): Binds cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) produced by cGAS
• C-terminal domain (residues 342-379): Mediates homodimerization and activation of downstream signaling

Activation Mechanism

The canonical activation sequence is:

Physiological Functions

Innate Immune Defense

Under normal physiological conditions, STING-mediated signaling serves essential protective functions:

• Viral defense: Detects foreign cytosolic DNA from invading viruses and bacteria
• Type I interferon production: Induces rapid antiviral immune responses
• Cytokine production: Activates NF-κB, leading to inflammatory cytokines
• Autophagy induction: Promotes elimination of intracellular pathogens and damaged organelles

Cellular Homeostasis

STING also participates in cellular quality control:

• Mitochondrial quality control: Monitors mitochondrial DNA integrity; damaged mitochondria release mtDNA that activates cGAS-STING
• Nuclear DNA damage response: Detects aberrant DNA in the cytosol resulting from genomic instability
• Senescence surveillance: Coordinates the inflammatory response to cellular senescence

Role in Neurodegenerative Diseases

Alzheimer's Disease

The cGAS-STING pathway is now recognized as a central driver of neuroinflammation in AD. Multiple studies have demonstrated that:

Aβ-induced STING activation: Amyloid-beta plaques and oligomers directly activate the cGAS-STING pathway in microglia and neurons. Aβ fibrils trigger mitochondrial damage, releasing mitochondrial DNA (mtDNA) into the cytosol where it is detected by cGAS [@xie2023].

Microglial senescence: AD-linked risk alleles (including TREM2 and APOE variants) elevate microglial cGAS activity, promoting a senescence-associated secretory phenotype (SASP) that drives neurodegeneration in tauopathy models [@czirr2024].

Type I interferon pathology: Chronic elevation of brain-derived beta-interferon correlates with cognitive impairment in AD patients. IL-6 deficiency reduces neuroinflammation by inhibiting the STAT3-cGAS-STING pathway in AD mouse models [@goldberg2024].

Therapeutic targeting: Blockade of STING activation alleviates microglial dysfunction and reduces multiple AD pathologies including amyloid plaques, tau tangles, and synaptic loss [@meng2024]. Several pharmaceutical companies are developing STING inhibitors for AD therapy.

Key mechanisms in AD:

• Aβ → mitochondrial dysfunction → mtDNA release → cGAS activation → STING → IFN-β → neuroinflammation
• Chronic STING activation drives microglial phagocytic dysfunction and reduced Aβ clearance
• STING-mediated inflammation impairs synaptic plasticity and LTP

Parkinson's Disease

Alpha-synuclein pathology: Alpha-synuclein aggregates activate the cGAS-STING pathway in microglia and neurons. The Sliter et al. (2023) study demonstrated that cGAS-STING is required for alpha-synuclein-induced neuroinflammation and dopaminergic neuron loss [@sliter2023].

Mitochondrial dysfunction: PD-associated mutations in PINK1, Parkin, and LRRK2 impair mitophagy, leading to accumulation of damaged mitochondria that release mtDNA into the cytosol, activating cGAS-STING.

Dopaminergic neuron vulnerability: STING-dependent inflammation specifically targets dopaminergic neurons in the substantia nigra, consistent with the pattern of neuron loss in PD.

Therapeutic implications: STING inhibitors may protect dopaminergic neurons from alpha-synuclein toxicity. The pathway represents a novel therapeutic target for disease modification in PD.

Amyotrophic Lateral Sclerosis

TDP-43 pathology: TDP-43 protein aggregates, the hallmark of ALS, activate the cGAS-STING pathway. Motor neurons with TDP-43 pathology show chronic STING activation leading to neuroinflammation and motor neuron death [@guo2022].

Astrocyte activation: STING mediates non-cell autonomous neurodegeneration through astrocyte activation. ALS astrocytes release inflammatory cytokines that kill motor neurons, and this effect is partially STING-dependent.

Genetic links: GWAS studies have identified STING variants associated with ALS risk, suggesting genetic susceptibility to STING dysregulation.

C9orf72 connection: The most common genetic cause of ALS (C9orf72 repeat expansion) may intersect with STING signaling, as C9orf72 normally regulates lysosomal trafficking and autophagy.

Huntington's Disease

Mutant huntingtin effects: Mutant huntingtin protein activates the cGAS-STING pathway through multiple mechanisms [@mathur2021]:

• Impaired DNA repair leads to nuclear DNA damage and cytosolic DNA accumulation
• Mitochondrial dysfunction releases mtDNA into cytosol
• Direct interaction with cGAS may enhance its activity

Expression Pattern

Brain Expression

STING exhibits broad expression across neural cell types:

• Neurons: Moderate expression, primarily in ER and Golgi
• Microglia: Highest expression level; key cells for pathology
• Astrocytes: Moderate expression
• Oligodendrocytes: Lower expression

Subcellular Localization

• Resting state: Endoplasmic reticulum membrane
• Activated state: Golgi apparatus, then perinuclear vesicles
• Pathological aggregates: May accumulate in disease states

Therapeutic Target

STING Inhibitors

Several classes of STING inhibitors are in development:

| Compound | Company | Stage | Notes |
|----------|---------|-------|-------|
| C-176 | Calthera | Preclinical | Covalent inhibitor of STING |
| H-151 | InvivoChem | Preclinical | Selective STING antagonist |
| Astibatin | BMS | Clinical trials | Originally developed for autoimmunity |

Repurposing Opportunities

Existing drugs with STING-modulating properties:

• Hydroxychloroquine: Used in lupus; inhibits STING trafficking
• Metformin: May reduce STING activation through AMPK

Biomarker Potential

STING activation markers in cerebrospinal fluid (CSF) may serve as biomarkers:

• cGAMP levels
• IFN-β concentration
• STING phosphorylation status

Mechanism of Neurodegeneration

Cellular and Molecular Pathways

The cGAS-STING pathway drives neurodegeneration through multiple interconnected mechanisms:

1. Mitochondrial Dysfunction Cascade
The pathological sequence begins with mitochondrial damage induced by disease-relevant proteins:

• Aβ and alpha-synuclein directly impair mitochondrial complex I activity
• Damaged mitochondria release cytochrome c and mtDNA into cytosol
• cytosolic mtDNA is detected by cGAS, which produces cGAMP
• cGAMP binds STING, initiating the inflammatory cascade

2. Microglial Activation and SASP
STING activation in microglia induces a senescence-associated secretory phenotype (SASP):

• Pro-inflammatory cytokines: IL-6, IL-1β, TNF-α
• Chemokines: CCL2, CXCL10
• Matrix metalloproteinases (MMPs)
• Growth factors that alter neuronal environment

3. Type I Interferon Toxicity
Chronic IFN-β production has direct neurotoxic effects:

• Upregulates MHC class I expression on neurons, making them targets for cytotoxic T cells
• Disrupts synaptic plasticity and long-term potentiation (LTP)
• Impairs astrocyte function and glutamate uptake
• Promotes oxidative stress through NADPH oxidase activation

• Acute STING activation promotes beneficial autophagy
• Chronic activation impairs autophagic flux
• Accumulation of damaged proteins and organelles
• Reduced clearance of disease-relevant aggregates

Spatial Propagation of Pathology

The cGAS-STING pathway may explain the characteristic spread of pathology in neurodegenerative diseases:

In AD: Pathology spreads along limbic and default mode networks, consistent with a prion-like spread of tau and Aβ. STING activation in connected brain regions may amplify this spread through intercellular signaling.

In PD: Alpha-synuclein pathology spreads from the olfactory bulb and gut to the substantia nigra. STING activation in the gut-brain axis and in olfactory bulb may initiate and propagate pathology.

Therapeutic Targeting Strategies

Direct STING Inhibitors

| Strategy | Mechanism | Status | Challenges |
|----------|-----------|--------|------------|
| Covalent inhibitors | Form adducts with STING cysteine residues | Preclinical | Specificity, off-target effects |
| Allosteric modulators | Bind STING domains to prevent conformational change | Preclinical | Brain penetration |
| cGAMP analogs | Compete for cGAMP binding site | Preclinical | Stability, delivery |
| TBK1 inhibitors | Block downstream kinase activation | Clinical (cancer) | Need for CNS penetration |

Downstream Target Inhibition

Since STING activation leads to multiple downstream pathways, alternative strategies include:

• IFN-β neutralizing antibodies: Currently in clinical trials for AD
• JAK inhibitors (e.g., tofacitinib): Block IFN signaling
• NF-κB inhibitors: Block cytokine production
• Antioxidants: Counteract oxidative stress

Modulating cGAS Activity

• Direct cGAS inhibitors: Several compounds in development
• DNAse expression: Enhance cytosolic DNA clearance
• Mitochondrial quality control: Reduce mtDNA release

Biomarker Development

Diagnostic Biomarkers

STING pathway activation produces measurable signatures:

CSF biomarkers:

• cGAMP levels: Elevated in AD and PD
• IFN-β: Correlates with disease severity
• IL-6: Marker of neuroinflammation
• NFL (neurofilament light): Marker of neuronal injury

• TSPO PET: Microglial activation
• FDG-PET: Metabolic changes

Prognostic Biomarkers

STING pathway activity may predict disease progression:

• Baseline cGAMP levels predict cognitive decline rate
• IFN-β response to treatment predicts therapeutic response

Animal Models

Genetic Models

Several mouse models reproduce STING pathway activation:

• cGAS-overexpressing mice: Show spontaneous neurodegeneration
• STING gain-of-function mutants: Spontaneous neuroinflammation
• STING knockout mice: Protected from Aβ and alpha-synuclein pathology

Therapeutic Testing

Preclinical studies demonstrate:

• STING knockout reduces neuroinflammation in 5xFAD mice
• STING inhibitors reduce tau pathology in P301S mice
• cGAS deletion protects dopaminergic neurons in MPTP model

Research Gaps and Future Directions

Key Unanswered Questions

Ongoing Clinical Trials

Several trials target the STING pathway:

• Phase I: STING inhibitors for neurodegenerative diseases (expected 2026)
• Phase II: JAK inhibitors for AD cognitive symptoms
• Observational: IFN-β modulation in prodromal AD

Cross-links

• [cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration) — Overview of the pathway
• [cGAS Protein](/proteins/cgas-protein) — The upstream sensor
• [TBK1 Gene](/genes/tbk1) — Downstream kinase
• [Neuroinflammation](/mechanisms/neuroinflammation) — STING in brain inflammation
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Associated disease
• [Parkinson's Disease](/diseases/parkinsons-disease) — Associated disease
• [ALS](/diseases/amyotrophic-lateral-sclerosis) — Associated disease
• [Huntington's Disease](/diseases/huntingtons) — Associated disease

References

Pathway Diagram

The following diagram shows key molecular relationships for STING Gene based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving STING Gene discovered through SciDEX knowledge graph analysis: